These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 34458319)
1. Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1-Based Therapy. Li H; An X; Huang R; Li L; Chu C; Yang W; Qin Z; Liu Z; Zhou F; Xue C; Shi Y Front Mol Biosci; 2021; 8():621883. PubMed ID: 34458319 [No Abstract] [Full Text] [Related]
2. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. Fornarini G; Rebuzzi SE; Banna GL; Calabrò F; Scandurra G; De Giorgi U; Masini C; Baldessari C; Naglieri E; Caserta C; Manacorda S; Maruzzo M; Milella M; Buttigliero C; Tambaro R; Ermacora P; Morelli F; Nolè F; Astolfi C; Sternberg CN ESMO Open; 2021 Jun; 6(3):100118. PubMed ID: 33984678 [TBL] [Abstract][Full Text] [Related]
3. Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer. Pirlog CF; Cotan HT; Parosanu A; Orlov Slavu C; Popa AM; Iaciu C; Olaru M; Oprita AV; Nita I; Nitipir C Cureus; 2022 Jul; 14(7):e26843. PubMed ID: 35974841 [TBL] [Abstract][Full Text] [Related]
4. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. Banna GL; Signorelli D; Metro G; Galetta D; De Toma A; Cantale O; Banini M; Friedlaender A; Pizzutillo P; Garassino MC; Addeo A Transl Lung Cancer Res; 2020 Aug; 9(4):1533-1542. PubMed ID: 32953525 [TBL] [Abstract][Full Text] [Related]
5. The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors. Chen L; Zhao R; Sun H; Huang R; Pan H; Zuo Y; Zhang L; Xue Y; Li X; Song H Front Pharmacol; 2022; 13():833584. PubMed ID: 35795575 [No Abstract] [Full Text] [Related]
6. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study. Auvray M; Elaidi R; Ozguroglu M; Guven S; Gauthier H; Culine S; Caty A; Dujardin C; Auclin E; Thibaut C; Combe P; Tartour E; Oudard S Clin Genitourin Cancer; 2017 Jun; 15(3):e469-e476. PubMed ID: 27964892 [TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy. Li L; Pi C; Yan X; Lu J; Yang X; Wang C; Li X; Zhang S; Zhang Z; Sun Y; Hu Y Front Oncol; 2021; 11():697865. PubMed ID: 34692478 [TBL] [Abstract][Full Text] [Related]
8. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study. Ruiz-Bañobre J; Molina-Díaz A; Fernández-Calvo O; Fernández-Núñez N; Medina-Colmenero A; Santomé L; Lázaro-Quintela M; Mateos-González M; García-Cid N; López-López R; Vázquez S; Anido-Herranz U ESMO Open; 2021 Apr; 6(2):100090. PubMed ID: 33740735 [TBL] [Abstract][Full Text] [Related]
9. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355 [TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A Clin Med Insights Oncol; 2021; 15():11795549211021667. PubMed ID: 34290538 [TBL] [Abstract][Full Text] [Related]
11. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma. Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095 [TBL] [Abstract][Full Text] [Related]
12. Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. Nakamura K; Ishiyama Y; Nemoto Y; Ishihara H; Tachibana H; Fukuda H; Shinmura H; Hashimoto Y; Yoshida K; Iizuka J; Ishida H; Kondo T; Takagi T Int J Clin Oncol; 2023 Jul; 28(7):913-921. PubMed ID: 37103730 [TBL] [Abstract][Full Text] [Related]
13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
14. Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. Alessandrino F; Gujrathi R; Nassar AH; Alzaghal A; Ravi A; McGregor B; Sonpavde G; Shinagare AB Eur Urol Oncol; 2020 Oct; 3(5):680-686. PubMed ID: 31412003 [TBL] [Abstract][Full Text] [Related]
15. Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma. Ali WAS; Huang X; Wu Y; Ma Y; Pan H; Liao J; Yang Z; Hong S; Yang Y; Huang Y; Zhao Y; Fang W; Zhao H; Zhang L Cancer Control; 2023; 30():10732748221148912. PubMed ID: 36592162 [TBL] [Abstract][Full Text] [Related]
16. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. Lalani AA; Xie W; Martini DJ; Steinharter JA; Norton CK; Krajewski KM; Duquette A; Bossé D; Bellmunt J; Van Allen EM; McGregor BA; Creighton CJ; Harshman LC; Choueiri TK J Immunother Cancer; 2018 Jan; 6(1):5. PubMed ID: 29353553 [TBL] [Abstract][Full Text] [Related]
17. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987 [TBL] [Abstract][Full Text] [Related]
18. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy. Gao Y; Zhang Z; Li Y; Chen S; Lu J; Wu L; Ma Z; Hu Y; Zhang G Front Oncol; 2022; 12():834564. PubMed ID: 35494073 [TBL] [Abstract][Full Text] [Related]
19. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer. Wang X; Cao L; Li S; Wang F; Huang D; Jiang R J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599 [No Abstract] [Full Text] [Related]
20. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. Pierro M; Baldini C; Auclin E; Vincent H; Varga A; Martin Romano P; Vuagnat P; Besse B; Planchard D; Hollebecque A; Champiat S; Marabelle A; Michot JM; Massard C; Mezquita L Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]